{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:38:19Z","timestamp":1792028299636,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,12,7]],"date-time":"2013-12-07T00:00:00Z","timestamp":1386374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00467-013-2696-0","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T02:09:37Z","timestamp":1386295777000},"page":"863-869","source":"Crossref","is-referenced-by-count":37,"title":["Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature"],"prefix":"10.1007","volume":"29","author":[{"given":"Rebecca L.","family":"Ruebner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Copelovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas F.","family":"Evageliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Denburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean B.","family":"Belasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard S.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,7]]},"reference":[{"key":"2696_CR1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","volume":"24","author":"G Bollee","year":"2009","unstructured":"Bollee G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P, Noel LH, Knebelmann B (2009) Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 24:682\u2013685","journal-title":"Nephrol Dial Transplant"},{"key":"2696_CR2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000241551","volume":"2","author":"YS Chen","year":"2009","unstructured":"Chen YS, Chen CL, Wang JS (2009) Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib. Case Rep Oncol 2:172\u2013176","journal-title":"Case Rep Oncol"},{"key":"2696_CR3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4143\/crt.2008.40.4.211","volume":"40","author":"MK Choi","year":"2008","unstructured":"Choi MK, Hong JY, Jang JH, Lim HY (2008) TTP-HUS associated with sunitinib. Cancer Res Treat 40:211\u2013213","journal-title":"Cancer Res Treat"},{"key":"2696_CR4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","volume":"8","author":"C Frangie","year":"2007","unstructured":"Frangie C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D (2007) Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 8:177\u2013178","journal-title":"Lancet Oncol"},{"key":"2696_CR5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/0971-4065.107215","volume":"23","author":"PK Jha","year":"2013","unstructured":"Jha PK, Vankalakunti M, Siddini V, Bonu R, Prakash GK, Babu K, Ballal HS (2013) Sunitinib induced nephrotic syndrome and thrombotic microangiopathy. Indian J Nephrol 23:67\u201370","journal-title":"Indian J Nephrol"},{"key":"2696_CR6","doi-asserted-by":"crossref","first-page":"c312","DOI":"10.1159\/000319885","volume":"117","author":"KD Jhaveri","year":"2011","unstructured":"Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG (2011) Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 117:c312\u2013c319","journal-title":"Nephron Clin Pract"},{"key":"2696_CR7","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/annonc\/mdm454","volume":"18","author":"E Kapiteijn","year":"2007","unstructured":"Kapiteijn E, Brand A, Kroep J, Gelderblom H (2007) Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 18:1745\u20131747","journal-title":"Ann Oncol"},{"key":"2696_CR8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","volume":"100","author":"TV Patel","year":"2008","unstructured":"Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD (2008) A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100:282\u2013284","journal-title":"J Natl Cancer Inst"},{"key":"2696_CR9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s10157-011-0543-9","volume":"16","author":"D Takahashi","year":"2012","unstructured":"Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T (2012) Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol 16:310\u2013315","journal-title":"Clin Exp Nephrol"},{"key":"2696_CR10","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.ajkd.2013.01.022","volume":"61","author":"E Wallace","year":"2013","unstructured":"Wallace E, Lyndon W, Chumley P, Jaimes EA, Fatima H (2013) Dasatinib-induced nephrotic-range proteinuria. Am J Kidney Dis 61:1026\u20131031","journal-title":"Am J Kidney Dis"},{"key":"2696_CR11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ki.2008.288","volume":"74","author":"JS Obhrai","year":"2008","unstructured":"Obhrai JS, Patel TV, Humphreys BD (2008) The case \/ progressive hypertension and proteinuria on anti-angiogenic therapy. Kidney Int 74:685\u2013686","journal-title":"Kidney Int"},{"key":"2696_CR12","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1345\/aph.1R160","volume":"46","author":"N Turan","year":"2012","unstructured":"Turan N, Benekli M, Ozturk SC, Inal S, Memis L, Guz G, Cetin B, Buyukberber S (2012) Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. Ann Pharmacother 46:e27","journal-title":"Ann Pharmacother"},{"key":"2696_CR13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","volume":"346","author":"DG Savage","year":"2002","unstructured":"Savage DG, Antman KH (2002) Imatinib mesylate\u2013a new oral targeted therapy. N Engl J Med 346:683\u2013693","journal-title":"N Engl J Med"},{"key":"2696_CR14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/asheducation-2011.1.361","volume":"2011","author":"SP Hunger","year":"2011","unstructured":"Hunger SP (2011) Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia. Hematology Am Soc Hematol Educ Program 2011:361\u2013365","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2696_CR15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ctrv.2010.08.005","volume":"37","author":"S Oudard","year":"2011","unstructured":"Oudard S, Beuselinck B, Decoene J, Albers P (2011) Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat Rev 37:178\u2013184","journal-title":"Cancer Treat Rev"},{"key":"2696_CR16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/07357900701513074","volume":"25","author":"JM Skolnik","year":"2007","unstructured":"Skolnik JM, Adamson PC (2007) Tyrosine kinase inhibitors in pediatric malignancies. Cancer Invest 25:606\u2013612","journal-title":"Cancer Invest"},{"key":"2696_CR17","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584\u20133590","journal-title":"J Clin Oncol"},{"key":"2696_CR18","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15:6232\u20136240","journal-title":"Clin Cancer Res"},{"key":"2696_CR19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/08860220903391226","volume":"32","author":"S Ozkurt","year":"2010","unstructured":"Ozkurt S, Temiz G, Acikalin MF, Soydan M (2010) Acute renal failure under dasatinib therapy. Ren Fail 32:147\u2013149","journal-title":"Ren Fail"},{"key":"2696_CR20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.leukres.2008.07.029","volume":"33","author":"SA Holstein","year":"2009","unstructured":"Holstein SA, Stokes JB, Hohl RJ (2009) Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res 33:344\u2013347","journal-title":"Leuk Res"},{"key":"2696_CR21","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1093\/ndt\/gfg372","volume":"18","author":"G Boner","year":"2003","unstructured":"Boner G, Cox AJ, Kelly DJ, Tobar A, Bernheim J, Langham RG, Cooper ME, Gilbert RE (2003) Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease? Nephrol Dial Transplant 18:2293\u20132299","journal-title":"Nephrol Dial Transplant"},{"key":"2696_CR22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1681\/ASN.V75661","volume":"7","author":"K Shulman","year":"1996","unstructured":"Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF (1996) Expression of vascular permeability factor (VPF\/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 7:661\u2013666","journal-title":"J Am Soc Nephrol"},{"key":"2696_CR23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129\u20131136","journal-title":"N Engl J Med"},{"key":"2696_CR24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49:186\u2013193","journal-title":"Am J Kidney Dis"},{"key":"2696_CR25","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21:1381\u20131389","journal-title":"J Am Soc Nephrol"},{"key":"2696_CR26","first-page":"F240","volume":"268","author":"M Simon","year":"1995","unstructured":"Simon M, Grone HJ, Johren O, Kullmer J, Plate KH, Risau W, Fuchs E (1995) Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 268:F240\u2013F250","journal-title":"Am J Physiol"},{"key":"2696_CR27","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1074\/jbc.C300012200","volume":"278","author":"H Sugimoto","year":"2003","unstructured":"Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278:12605\u201312608","journal-title":"J Biol Chem"},{"key":"2696_CR28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707\u2013716","journal-title":"J Clin Invest"},{"key":"2696_CR29","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1053\/j.ajkd.2010.06.006","volume":"56","author":"RJ Goldberg","year":"2010","unstructured":"Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM (2010) The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis 56:1168\u20131174","journal-title":"Am J Kidney Dis"},{"key":"2696_CR30","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ki.2011.288","volume":"80","author":"P Kandula","year":"2011","unstructured":"Kandula P, Agarwal R (2011) Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int 80:1271\u20131277","journal-title":"Kidney Int"},{"key":"2696_CR31","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/sj.ki.5000341","volume":"69","author":"V Audard","year":"2006","unstructured":"Audard V, Larousserie F, Grimbert P, Abtahi M, Sotto JJ, Delmer A, Boue F, Nochy D, Brousse N, Delarue R, Remy P, Ronco P, Sahali D, Lang P, Hermine O (2006) Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature. Kidney Int 69:2251\u20132260","journal-title":"Kidney Int"},{"key":"2696_CR32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0002-9343(86)90049-5","volume":"80","author":"DJ Dabbs","year":"1986","unstructured":"Dabbs DJ, Striker LM, Mignon F, Striker G (1986) Glomerular lesions in lymphomas and leukemias. Am J Med 80:63\u201370","journal-title":"Am J Med"},{"key":"2696_CR33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10157-006-0437-4","volume":"10","author":"A Mallouk","year":"2006","unstructured":"Mallouk A, Pham PT, Pham PC (2006) Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol 10:284\u2013289","journal-title":"Clin Exp Nephrol"},{"key":"2696_CR34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2141.2001.02704.x","volume":"113","author":"S Fontana","year":"2001","unstructured":"Fontana S, Gerritsen HE, Kremer Hovinga J, Furlan M, Lammle B (2001) Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol 113:100\u2013102","journal-title":"Br J Haematol"},{"key":"2696_CR35","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1055\/s-2005-925475","volume":"31","author":"L Qu","year":"2005","unstructured":"Qu L, Kiss JE (2005) Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost 31:691\u2013699","journal-title":"Semin Thromb Hemost"},{"key":"2696_CR36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00467-003-1119-z","volume":"18","author":"H Hahn","year":"2003","unstructured":"Hahn H, Ha IS, Choi HS, Shin HY, Cheong HI, Ahn HS, Choi Y (2003) Acute leukemia: an association with atypical hemolytic uremic syndrome. Pediatr Nephrol 18:703\u2013705","journal-title":"Pediatr Nephrol"},{"key":"2696_CR37","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/1097-0142(19950301)75:5<1167::AID-CNCR2820750517>3.0.CO;2-1","volume":"75","author":"H Sill","year":"1995","unstructured":"Sill H, Hofler G, Kaufmann P, Horina J, Spuller E, Kleinert R, Beham-Schmid C (1995) Angiotropic large cell lymphoma presenting as thrombotic microangiopathy (thrombotic thrombocytopenic purpura). Cancer 75:1167\u20131170","journal-title":"Cancer"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-013-2696-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-013-2696-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-013-2696-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T23:02:00Z","timestamp":1647644520000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-013-2696-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,7]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["2696"],"URL":"https:\/\/doi.org\/10.1007\/s00467-013-2696-0","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,7]]}}}